
argenx (ARGX) Stock Forecast & Price Target
argenx (ARGX) Analyst Ratings
Bulls say
Argenx has demonstrated a positive financial trajectory characterized by breakeven operating profits in Q3 2024 and a substantial increase in global product net sales, which reached $737 million in Q4 2024, marking a 29% quarter-over-quarter and 97% year-over-year growth. The company's commitment to innovation is underscored by its ongoing investment in research and development, which accounted for approximately 30% of revenue, aimed at expanding its pipeline targeting rare autoimmune diseases. Moreover, with strong health data supporting its lead product, Vyvgart, and its recent approvals for additional indications, Argenx is well-positioned for sustained growth in the lucrative biopharmaceutical market.
Bears say
Argenx has experienced a slight decrease in R&D expenses, with a 3.0% year-over-year drop to $297.2 million in 4Q23, which raises concerns about the company's financial commitment to innovation amid competitive pressures. The company faces significant risks, including lower-than-anticipated sales growth for its lead product, Vyvgart, and potential setbacks in ongoing clinical trials, which could negatively impact future revenues. Additionally, market dynamics suggest a looming threat from increased competition, along with macroeconomic factors that could further hinder growth prospects in Argenx's pipeline for treating rare autoimmune diseases.
This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.
argenx (ARGX) Analyst Forecast & Price Prediction
Start investing in argenx (ARGX)
Order type
Buy in
Order amount
Est. shares
0 shares